These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37730182)

  • 1. Protein Kinase Signaling Networks Driven by Oncogenic Gq/11 in Uveal Melanoma Identified by Phosphoproteomic and Bioinformatic Analyses.
    Onken MD; Erdmann-Gilmore P; Zhang Q; Thapa K; King E; Kaltenbronn KM; Noda SE; Makepeace CM; Goldfarb D; Babur Ö; Townsend RR; Blumer KJ
    Mol Cell Proteomics; 2023 Nov; 22(11):100649. PubMed ID: 37730182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting primary and metastatic uveal melanoma with a G protein inhibitor.
    Onken MD; Makepeace CM; Kaltenbronn KM; Choi J; Hernandez-Aya L; Weilbaecher KN; Piggott KD; Rao PK; Yuede CM; Dixon AJ; Osei-Owusu P; Cooper JA; Blumer KJ
    J Biol Chem; 2021; 296():100403. PubMed ID: 33577798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic Gq/11 signaling acutely drives and chronically sustains metabolic reprogramming in uveal melanoma.
    Onken MD; Noda SE; Kaltenbronn KM; Frankfater C; Makepeace CM; Fettig N; Piggott KD; Custer PL; Ippolito JE; Blumer KJ
    J Biol Chem; 2022 Jan; 298(1):101495. PubMed ID: 34919964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling.
    Park JJ; Stewart A; Irvine M; Pedersen B; Ming Z; Carlino MS; Diefenbach RJ; Rizos H
    Cancer Gene Ther; 2022 Oct; 29(10):1384-1393. PubMed ID: 35352024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.
    Wu X; Zhu M; Fletcher JA; Giobbie-Hurder A; Hodi FS
    PLoS One; 2012; 7(1):e29622. PubMed ID: 22253748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma.
    Chen X; Wu Q; Depeille P; Chen P; Thornton S; Kalirai H; Coupland SE; Roose JP; Bastian BC
    Cancer Cell; 2017 May; 31(5):685-696.e6. PubMed ID: 28486107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Uveal Melanoma: Molecular and Genetic Mechanisms of Development and Therapeutic Approaches].
    Zhilnikova MV; Troitskaya OS; Novak DD; Atamanov VV; Koval OA
    Mol Biol (Mosk); 2024; 58(2):189-203. PubMed ID: 39355878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.
    Chen X; Wu Q; Tan L; Porter D; Jager MJ; Emery C; Bastian BC
    Oncogene; 2014 Sep; 33(39):4724-34. PubMed ID: 24141786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.
    Yu FX; Luo J; Mo JS; Liu G; Kim YC; Meng Z; Zhao L; Peyman G; Ouyang H; Jiang W; Zhao J; Chen X; Zhang L; Wang CY; Bastian BC; Zhang K; Guan KL
    Cancer Cell; 2014 Jun; 25(6):822-30. PubMed ID: 24882516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of Darovasertib (NVP-LXS196), a Pan-PKC Inhibitor for the Treatment of Metastatic Uveal Melanoma.
    Visser M; Papillon JPN; Luzzio M; LaMarche MJ; Fan J; Michael W; Wang D; Zhang A; Straub C; Mathieu S; Kato M; Palermo M; Chen C; Ramsey T; Joud C; Barrett R; Vattay A; Guo R; Bric A; Chung F; Liang G; Romanowski MJ; Lam J; Thohan S; Atassi F; Wylie A; Cooke VG
    J Med Chem; 2024 Jan; 67(2):1447-1459. PubMed ID: 38198520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MITF deficiency accelerates GNAQ-driven uveal melanoma.
    Phelps GB; Hagen HR; Amsterdam A; Lees JA
    Proc Natl Acad Sci U S A; 2022 May; 119(19):e2107006119. PubMed ID: 35512098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of chromosomal aberrations and GNAQ, GNA11 and BAP1 mutations in uveal melanoma.
    Staby KM; Gravdal K; Mørk SJ; Heegaard S; Vintermyr OK; Krohn J
    Acta Ophthalmol; 2018 Feb; 96(1):31-38. PubMed ID: 28444874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.
    Wu X; Li J; Zhu M; Fletcher JA; Hodi FS
    Mol Cancer Ther; 2012 Sep; 11(9):1905-14. PubMed ID: 22653968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Copper ionophore elesclomol selectively targets GNAQ/11-mutant uveal melanoma.
    Li Y; Yang J; Zhang Q; Xu S; Sun W; Ge S; Xu X; Jager MJ; Jia R; Zhang J; Fan X
    Oncogene; 2022 Jul; 41(27):3539-3553. PubMed ID: 35697803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK.
    Feng X; Arang N; Rigiracciolo DC; Lee JS; Yeerna H; Wang Z; Lubrano S; Kishore A; Pachter JA; König GM; Maggiolini M; Kostenis E; Schlaepfer DD; Tamayo P; Chen Q; Ruppin E; Gutkind JS
    Cancer Cell; 2019 Mar; 35(3):457-472.e5. PubMed ID: 30773340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palmitoylation of GNAQ/11 is critical for tumor cell proliferation and survival in GNAQ/11-mutant uveal melanoma.
    Zhang Y; Zhang B; Li Y; Dai Y; Li J; Li D; Xia Z; Zhang J; Liu P; Chen M; Jiao B; Ren R
    Front Med; 2022 Oct; 16(5):784-798. PubMed ID: 35997986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.
    Musi E; Ambrosini G; de Stanchina E; Schwartz GK
    Mol Cancer Ther; 2014 May; 13(5):1044-53. PubMed ID: 24563540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional characterization of uveal melanoma oncogenes.
    Ma J; Weng L; Bastian BC; Chen X
    Oncogene; 2021 Jan; 40(4):806-820. PubMed ID: 33262460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma.
    Arang N; Lubrano S; Ceribelli M; Rigiracciolo DC; Saddawi-Konefka R; Faraji F; Ramirez SI; Kim D; Tosto FA; Stevenson E; Zhou Y; Wang Z; Bogomolovas J; Molinolo AA; Swaney DL; Krogan NJ; Yang J; Coma S; Pachter JA; Aplin AE; Alessi DR; Thomas CJ; Gutkind JS
    Cell Rep Med; 2023 Nov; 4(11):101244. PubMed ID: 37858338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity in Mitogen-Activated Protein Kinase (MAPK) Pathway Activation in Uveal Melanoma With Somatic GNAQ and GNA11 Mutations.
    Boru G; Cebulla CM; Sample KM; Massengill JB; Davidorf FH; Abdel-Rahman MH
    Invest Ophthalmol Vis Sci; 2019 Jun; 60(7):2474-2480. PubMed ID: 31173078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.